Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

(2019) Jesus Feliu et al.   BONE MARROW TRANSPLANTATION

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial

(2018) Merav Bar et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report

(2015) Paul J. Martin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation for Pediatric Hematologic Malignancies

(2015) Biljana Horn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial

(2014) S R Solomon et al.   BONE MARROW TRANSPLANTATION

Outcome of Donor Lymphocyte Infusion after T Cell–depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes

(2012) Pramila Krishnamurthy et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A disease risk index for patients undergoing allogeneic stem cell transplantation

(2012) P. Armand et al.   BLOOD

Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation

(2011) E. Rettinger et al.   BLOOD

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

(2011) M. Jagasia et al.   BLOOD

Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure

(2011) Sajir G. Mohamedbhai et al.   BRITISH JOURNAL OF HAEMATOLOGY

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

(2010) A. J. Mead et al.   BLOOD

Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence

(2010) Koen van Besien et al.   LEUKEMIA & LYMPHOMA

Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse

(2009) Daniel J. Weisdorf et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD